Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Toxicologic Pathology|September 17, 2022
Pathology of Bone: Changes Associated With Different Classes of CompoundsKathryn E Gropp
Toxicologic Pathology|October 17, 2017
Effects on Cancellous Bone in the MetaphysisKathryn E Gropp
Toxicologic Pathology|October 17, 2017
Skeletal Muscle ToolboxKathryn E Gropp
Toxicologic Pathology|November 7, 2017
A Brief Overview of the STP 36th Annual Symposium: Musculoskeletal SystemKathryn E Gropp, Michael C Boyle
Toxicologic Pathology|November 6, 2016
A Brief Overview of the STP 35th Annual Symposium on the Basis and Relevance of Variation in Toxicologic ResponsesArmando R Irizarry, Kathryn E Gropp, Darlene Dixon
Toxicologic Pathology|May 18, 2018
Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic AssessmentsKathryn E Gropp, Cathy S Carlson, Mark G Evans, et al.
Diabetes, Obesity & Metabolism|June 3, 2017
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primatesAlbert M Kim, Veena R Somayaji, Jennifer Q Dong, et al.
Annals of the Rheumatic Diseases|July 7, 2016
Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear modelTimothy P LaBranche, Alison M Bendele, Brian C Omura, et al.
Toxicologic Pathology|April 23, 2016
Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular HypertrophyMichael E Dunn, Thomas G Manfredi, Kevin Agostinucci, et al.
BMC Medicine|July 14, 2007
Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceRichard T Hinkle, Frank R Lefever, Elizabeth T Dolan, et al.
Pageof 2